[go: up one dir, main page]

DK1073431T3 - Anvendelse af NMDA-antagonister til behandling af irritabel tarmsyndrom - Google Patents

Anvendelse af NMDA-antagonister til behandling af irritabel tarmsyndrom

Info

Publication number
DK1073431T3
DK1073431T3 DK99947024T DK99947024T DK1073431T3 DK 1073431 T3 DK1073431 T3 DK 1073431T3 DK 99947024 T DK99947024 T DK 99947024T DK 99947024 T DK99947024 T DK 99947024T DK 1073431 T3 DK1073431 T3 DK 1073431T3
Authority
DK
Denmark
Prior art keywords
bowel syndrome
irritable bowel
nmda antagonists
treat irritable
treat
Prior art date
Application number
DK99947024T
Other languages
Danish (da)
English (en)
Inventor
Aziz Asghar
Anne King
Jose Luis Cabero
Andrew Dray
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9801494A external-priority patent/SE9801494D0/xx
Priority claimed from SE9803954A external-priority patent/SE9803954D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1073431T3 publication Critical patent/DK1073431T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99947024T 1998-04-28 1999-04-28 Anvendelse af NMDA-antagonister til behandling af irritabel tarmsyndrom DK1073431T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use
SE9803954A SE9803954D0 (sv) 1998-11-18 1998-11-18 Novel use

Publications (1)

Publication Number Publication Date
DK1073431T3 true DK1073431T3 (da) 2004-10-04

Family

ID=26663287

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99947024T DK1073431T3 (da) 1998-04-28 1999-04-28 Anvendelse af NMDA-antagonister til behandling af irritabel tarmsyndrom

Country Status (20)

Country Link
EP (1) EP1073431B1 (no)
JP (1) JP2002512956A (no)
KR (1) KR100569777B1 (no)
CN (1) CN1200702C (no)
AR (1) AR016212A1 (no)
AT (1) ATE270545T1 (no)
AU (1) AU760783B2 (no)
BR (1) BR9909971A (no)
CA (1) CA2329328A1 (no)
DE (1) DE69918541T2 (no)
DK (1) DK1073431T3 (no)
ES (1) ES2221753T3 (no)
IL (1) IL138919A0 (no)
MY (1) MY121063A (no)
NO (1) NO20005386D0 (no)
NZ (1) NZ507436A (no)
PT (1) PT1073431E (no)
SA (1) SA99200482B1 (no)
TW (1) TW570793B (no)
WO (1) WO1999055323A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3582101A (en) * 2000-03-01 2001-09-12 Euro-Celtique S.A. The treatment of functional gastrointestinal disorders
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
JP2003081872A (ja) * 2001-09-13 2003-03-19 Nippon Oruganon Kk 掻痒治療薬
CA2518385A1 (en) * 2003-03-14 2004-09-23 Agi Therapeutics Ltd. Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
FR2865133B1 (fr) * 2004-01-19 2008-01-18 Rytek Compositions pour le traitement de pathologies digestives
CA3105834A1 (en) * 2018-07-06 2020-01-09 Algernon Pharmaceuticals Inc. Compounds for treatment of inflammatory bowel disease and methods thereof
KR102211282B1 (ko) 2019-11-20 2021-02-03 (주)파이브텍 데이터 라우팅 방법 및 이를 지원하는 스위치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition

Also Published As

Publication number Publication date
EP1073431B1 (en) 2004-07-07
JP2002512956A (ja) 2002-05-08
CA2329328A1 (en) 1999-11-04
PT1073431E (pt) 2004-10-29
KR20010043077A (ko) 2001-05-25
AR016212A1 (es) 2001-06-20
WO1999055323A1 (en) 1999-11-04
NZ507436A (en) 2003-09-26
TW570793B (en) 2004-01-11
CN1200702C (zh) 2005-05-11
DE69918541D1 (de) 2004-08-12
CN1307471A (zh) 2001-08-08
ES2221753T3 (es) 2005-01-01
DE69918541T2 (de) 2005-08-18
ATE270545T1 (de) 2004-07-15
NO20005386L (no) 2000-10-26
KR100569777B1 (ko) 2006-04-11
AU760783B2 (en) 2003-05-22
HK1033876A1 (en) 2001-09-28
EP1073431A1 (en) 2001-02-07
NO20005386D0 (no) 2000-10-26
IL138919A0 (en) 2001-11-25
BR9909971A (pt) 2000-12-26
AU4302499A (en) 1999-11-16
SA99200482B1 (ar) 2006-06-27
MY121063A (en) 2005-12-30

Similar Documents

Publication Publication Date Title
DK1126826T3 (da) Multipartikel-modificeret-frigivelsessammensætning af methylphenidat
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
PT1049695E (pt) Imidazotriazinonas 2-fenil substituidas enquanto inibidores de fosfodiesterase
FI981011L (fi) Uudet koostumukset
PT1250321E (pt) Composicao de gliburida
ID22764A (id) Komposisi pembersih abrasif-semprot
NO994626L (no) Substituerte benzamider
DE69930547D1 (de) Reinigungszusammensetzung
NO984662L (no) Vann-i-olje-emulsjonsgj°dningsstoff-sammensetninger
ID22838A (id) Oksazolidina sebagai antagonis 5-ht2a
DK1073431T3 (da) Anvendelse af NMDA-antagonister til behandling af irritabel tarmsyndrom
DK1187833T3 (da) Fremgangsmåde til fremstilling af thiamethoxam
PT1022396E (pt) Combinacao de duche
DK1326836T3 (da) Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
EP1023068A4 (en) ALPHA 1a ADRENORE RECEPTOR ANTAGONISTS
DK0947492T3 (da) Fremgangsmåde til fremstilling af citral
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
LU90483B1 (fr) Compositions nouvelles de m-thanesulfonate de parox-tine
DK1607090T3 (da) Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome)
DK1250148T3 (da) Anvendelse af FSH til behandling af infertilitet
EP1014973A4 (en) ALPHA-1a ADRENOR RECEPTOR ANTAGONISTS
FI980902A7 (fi) Levosimendaanin stabiileja koostumuksia
DK1012152T3 (da) Fremgangsmåde til fremstilling af oxazaphosphorin-2-aminer
PT1175417E (pt) Compostos substituidos de benzolactamas
ID30381A (id) Penggunaan arilalkanoilpiridazina